Short Communication | Published:

Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer

Oncogene volume 37, pages 263270 (11 January 2018) | Download Citation

Abstract

Tissue inhibitor of metalloproteinase-1 (TIMP-1), a member of the TIMP family (TIMP-1 to 4), is highly expressed in various types of cancer and forms a complex with its receptor CD63 and Integrin β1. However, the precise oncogenic mechanism of TIMP-1 remains unclear. Yes-associated protein (YAP) and transcriptional co-activator with PDZ binding motif (TAZ) are transcription co-activators enhancing the transcription of specific genes related to cell proliferation. But the mechanism of aberrant YAP/TAZ activation in cancer is not fully understood. Here, we showed that TIMP-1 activates YAP/TAZ as novel downstream targets to promote cell proliferation. The TIMP-1-CD63-Integrin β1 axis activates Src and promotes RhoA-mediated F-actin assembly, leading to LATS1/2 inactivation. This results in under-phosphorylation, protein stabilization and nuclear translocation of YAP/TAZ (YAP/TAZ activation); CTGF production; and cell proliferation. Furthermore, the TIMP-1-YAP/TAZ axis is aberrantly activated in various types of cancer cells or tissues. TIMP-1 knockdown inhibits cell proliferation through YAP/TAZ inactivation in cancer cells. This study found that TIMP-1 accelerates cell proliferation through YAP/TAZ activation in cancer, and suggests the TIMP-1-YAP/TAZ axis may be a novel potential drug target for cancer patients.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer. Int J Breast Cancer 2012; 2012: 10.

  2. 2.

    , , , , , et al. Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer 2011; 117: 517–525.

  3. 3.

    , , , , , et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol 2012; 14: 257–265.

  4. 4.

    , , . Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol 2013; 48: 899–905.

  5. 5.

    , , , , . Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-k signaling pathway independently of Akt phosphorylation. Mol Cancer 2013; 12: 22.

  6. 6.

    , , , , , et al. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res 2010; 34: 399–402.

  7. 7.

    , , , , , et al. Upregulated TIMP-1 correlates with poor prognosis of laryngeal squamous cell carcinoma. Int J Clin Exp Pathol 2013; 7: 246–254.

  8. 8.

    , , , , , et al. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol 2011; 13: 99–108.

  9. 9.

    , , , , , . Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients. Adv Med Sci 2013; 58: 227–234.

  10. 10.

    , , , , , et al. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway. J Exp Clin Cancer Res 2016; 35: 148.

  11. 11.

    , , , , . Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006; 25: 3934–3942.

  12. 12.

    , , , . Novel functions of TIMPs in cell signaling. Cancer Metast Rev 2006; 25: 99–113.

  13. 13.

    , , . The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 2015; 15: 73–79.

  14. 14.

    , . Regulation of the hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci 2013; 34: 581–589.

  15. 15.

    , , , , , et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012; 150: 780–791.

  16. 16.

    , , , , , et al. Tead and AP1 coordinate transcription and motility. Cell Rep 2016; 14: 1169–1180.

  17. 17.

    , , , , , et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 1962–1971.

  18. 18.

    , , . The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 2014; 94: 1287–1312.

  19. 19.

    , , , , , et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 2005; 18: 447–459.

  20. 20.

    , , , , , et al. β-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012; 151: 1457–1473.

  21. 21.

    , , , , . WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999; 18: 2551–2562.

  22. 22.

    , , , , , et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol 2015; 17: 1218–1227.

  23. 23.

    , , . Hippo pathway in organ size control tissue homeostasis, and cancer. Cell 2015; 163: 811–828.

  24. 24.

    , , , , , . The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 2008; 10: 1204–1212.

  25. 25.

    , , , , , et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal 2014; 7: ra42.

  26. 26.

    , , , , , et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer 2013; 13: 412–424.

  27. 27.

    , , , , , et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014; 25: 822–830.

  28. 28.

    , , , , , et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 2014; 25: 831–845.

  29. 29.

    , , , , , et al. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the hippo pathway. Oncogene 2015; 34: 3536–3346.

  30. 30.

    , , , , , et al. TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling. Sci Rep 2015; 5: 16492.

  31. 31.

    , , , . A hitchhiker’s guide to mechanobiology. Dev Cell 2011; 21: 35–47.

  32. 32.

    , , , , , et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120–1133.

  33. 33.

    , , , , , et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747–2761.

  34. 34.

    , , , , . A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev 2010; 24: 72–85.

  35. 35.

    , , , , , et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015; 519: 57–62.

  36. 36.

    , , , , . The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteosomal degradation. Proc Natl Acad Sci USA 2017; 114: 1678–1683.

  37. 37.

    , , . Disease implications of the Hippo/YAP pathway. Trends Mol Med 2015; 21: 212–222.

  38. 38.

    , , , , , et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling. Proc Natl Acad Sci USA 2012; 109: E309–E316.

  39. 39.

    , , , , , et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005; 65: 898–906.

  40. 40.

    , , , , , et al. MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev Cell 2013; 25: 402–416.

  41. 41.

    , , , , , et al. Integrin signaling regulates YAP and TAZ to control skin homeostasis. Development 2016; 143: 1674–1687.

  42. 42.

    , , , , , et al. PAK proteins and YAP-1 signaling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat Commun 2016; 7: 12502.

  43. 43.

    , , , , , et al. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. Nature 2016; 540: 579–582.

  44. 44.

    , . Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway. J Cell Biol 2015; 210: 503–515.

  45. 45.

    , , , , , et al. Characterization of hippo pathway components by gene inactivation. Mol Cell 2016; 64: 993–1008.

  46. 46.

    , , , , , et al. Role of YAP/TAZ in mechanotransduction. Nature 2011; 474: 179–183.

  47. 47.

    , , , , , et al. TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med 2012; 209: 479–494.

  48. 48.

    , , , , , et al. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol 2009; 95: 117–128.

  49. 49.

    , , , , . High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Res 2008; 28: 2715–2719.

  50. 50.

    , , , . TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer 2017; 17: 38–53.

  51. 51.

    , , , , , et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26: 1300–1305.

  52. 52.

    , , , , , et al. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res 2014; 124: 67–73.

  53. 53.

    , , , , , et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 2014; 25: 166–180.

  54. 54.

    , , , , , et al. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene 2015; 34: 3095–3106.

  55. 55.

    , , , , , et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 2014; 16: 357–366.

  56. 56.

    , , , . YAP/TAZ as therapeutic targets in cancer. Curr Opin Pharmacol 2016; 29: 26–33.

  57. 57.

    , , , , , et al. Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma. Sci Rep 2017; 7: 40187.

Download references

Acknowledgements

We thank Professor Koichiro Ozawa (Department of Pharmacotherapy, Hiroshima University) for valuable discussion and Professor Makiko Fujii (Department of Global Dental Medicine and Molecular Oncology, Hiroshima University) for providing us HA-tagged YAP-WT vector and anti-HA antibody. This work was funded, in part, by JSPS KAKENHI Grant Number JP25293373 and JP16H05503 to (TT) and 17K17084 to (TA). Hanako Umehara currently belongs to department of advanced prosthodontics, Hiroshima University.

Author information

Affiliations

  1. Department of Oral and Maxillofacial Pathobiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

    • T Ando
    • , D Charindra
    • , M Shrestha
    • , H Umehara
    • , M Miyauchi
    •  & T Takata
  2. Center of Oral Clinical Examination, Hiroshima University Hospital, Hiroshima, Japan

    • I Ogawa

Authors

  1. Search for T Ando in:

  2. Search for D Charindra in:

  3. Search for M Shrestha in:

  4. Search for H Umehara in:

  5. Search for I Ogawa in:

  6. Search for M Miyauchi in:

  7. Search for T Takata in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to T Takata.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/onc.2017.321

Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)